Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties

Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters

(2010) J. Weiss et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease

(2009) Jean-Charles Fruchart   ATHEROSCLEROSIS

Pharmacokinetics and dosage adjustment in patients with renal dysfunction

(2009) Roger K. Verbeeck et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pleiotropic effects of telmisartan: still more to come?

(2009) Ralf A Benndorf et al.   JOURNAL OF HYPERTENSION

Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes

(2009) Emi Kamiyama et al.   LIFE SCIENCES

Telmisartan pharmacokinetics in Japanese renal transplant recipients

(2008) Masatomo Miura et al.   CLINICA CHIMICA ACTA

No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects

(2008) Xin Guo et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Drug–Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug

(2008) KS Fenner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Liver-Specific Peroxisome Proliferator-Activated Receptor   Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan

(2008) M. Clemenz et al.   DIABETES

Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension

(2008) David H G Smith   DRUGS

Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?

(2008) Stephen C Benson et al.   JOURNAL OF HYPERTENSION

Thrombolytics for PE and right ventricular dysfunction

(2008) Syed Wamique Yusuf et al.   LANCET

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study

(2008) Hans-Christoph Diener et al.   LANCET NEUROLOGY

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells

(2007) Silvana Cianchetti et al.   ATHEROSCLEROSIS